Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Cavia porcellus | Kappa opioid receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Mu opioid receptor | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | diacylglycerol kinase | 0.016 | 0 | 0.5 |
Leishmania major | diacylglycerol kinase-like protein | 0.016 | 0 | 0.5 |
Trypanosoma brucei | Diacylglycerol kinase catalytic domain containing protein, putative | 0.016 | 0 | 0.5 |
Brugia malayi | diacylglycerol kinase | 0.016 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | bmru protein, putative | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, zeta, iota, putative | 0.016 | 0 | 0.5 |
Brugia malayi | hypothetical protein | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.016 | 0 | 0.5 |
Plasmodium falciparum | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.016 | 0 | 0.5 |
Onchocerca volvulus | 0.016 | 0 | 0.5 | |
Echinococcus multilocularis | sphingosine kinase 1 | 0.4104 | 1 | 1 |
Trypanosoma cruzi | diacylglycerol kinase-like protein, putative | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | Sphingosine kinase | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, zeta, iota, putative | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | Sphingosine kinase | 0.016 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase catalytic domain-containing protein | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Brugia malayi | Ceramide kinase | 0.016 | 0 | 0.5 |
Schistosoma mansoni | sphingoid long chain base kinase | 0.4104 | 1 | 1 |
Trypanosoma cruzi | Diacylglycerol kinase catalytic domain containing protein, putative | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | diacylglycerol kinase, epsilon, putative | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | bmru protein, putative | 0.016 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Mycobacterium tuberculosis | Conserved protein | 0.4104 | 1 | 1 |
Plasmodium falciparum | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Schistosoma mansoni | sphingosine kinase A B | 0.4104 | 1 | 1 |
Plasmodium vivax | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.4104 | 1 | 1 |
Onchocerca volvulus | Ceramide kinase 1 homolog | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | sphingosine kinase, putative | 0.016 | 0 | 0.5 |
Trichomonas vaginalis | sphingosine kinase, putative | 0.016 | 0 | 0.5 |
Trypanosoma cruzi | diacylglycerol kinase-like protein, putative | 0.016 | 0 | 0.5 |
Trypanosoma brucei | Sphingosine kinase | 0.016 | 0 | 0.5 |
Trypanosoma brucei | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Brugia malayi | Eye-specific diacylglycerol kinase | 0.016 | 0 | 0.5 |
Leishmania major | sphingosine kinase A, B, putative | 0.016 | 0 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.4104 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.4104 | 1 | 1 |
Brugia malayi | Diacylglycerol kinase protein 2 | 0.016 | 0 | 0.5 |
Leishmania major | diacylglycerol kinase, putative | 0.016 | 0 | 0.5 |
Toxoplasma gondii | diacylglycerol kinase accessory domain (presumed) domain-containing protein | 0.016 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AD50 (functional) | = 0.28 mg kg-1 | Antagonism of opioid analgesia using a mouse writhing model to block morphine (2.5 mg/kg) induced mu-opioid receptor (subcutaneously dosed) | ChEMBL. | 8410998 |
AD50 (functional) | = 0.28 mg kg-1 | Antagonism of opioid analgesia using a mouse writhing model to block morphine (2.5 mg/kg) induced mu-opioid receptor (subcutaneously dosed) | ChEMBL. | 8410998 |
AD50 (functional) | > 1.25 mg kg-1 | Antagonism of opioid analgesia using a mouse writhing model to block U-50,488 (2.5 mg/kg) induced kappa-opioid receptor subcutaneously | ChEMBL. | 8410998 |
AD50 (functional) | > 1.25 mg kg-1 | Antagonism of opioid analgesia using a mouse writhing model to block U-50,488 (2.5 mg/kg) induced kappa-opioid receptor subcutaneously | ChEMBL. | 8410998 |
AD50 (functional) | = 4.1 mg kg-1 | Tested for the antagonism of kappa opioid receptor diuresis at a dose of 0.08 mg/kg subcutaneously | ChEMBL. | 8410998 |
AD50 (functional) | = 4.1 mg kg-1 | Tested for the antagonism of kappa opioid receptor diuresis at a dose of 0.08 mg/kg subcutaneously | ChEMBL. | 8410998 |
Ki (binding) | = 2 nM | Binding affinity towards mu opioid receptor by displacement of [3H]-NAL from rat brain homogenates | ChEMBL. | 8410998 |
Ki (binding) | = 2 nM | Binding affinity towards mu opioid receptor by displacement of [3H]-NAL from rat brain homogenates | ChEMBL. | 8410998 |
Ki (binding) | = 22 nM | Binding affinity towards kappa-opioid receptor by displacement of [3H]-EKC at 10 nM from guinea pig cortical tissue | ChEMBL. | 8410998 |
Ki (binding) | = 22 nM | Binding affinity towards kappa-opioid receptor by displacement of [3H]-EKC at 10 nM from guinea pig cortical tissue | ChEMBL. | 8410998 |
Ki (binding) | = 70 nM | Binding affinity towards kappa-opioid receptor by displacement of [3H]-EKC at 100 nM from guinea pig cortical tissue | ChEMBL. | 8410998 |
Ki (binding) | = 70 nM | Binding affinity towards kappa-opioid receptor by displacement of [3H]-EKC at 100 nM from guinea pig cortical tissue | ChEMBL. | 8410998 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.